LncRNA CSMD1-1 promotes the progression of Hepatocellular Carcinoma by activating MYC signaling.

Emerging evidence suggests that long non-coding RNAs (lncRNA) play critical roles in the development and progression of diverse cancers including hepatocellular carcinoma (HCC), but the underlying molecular mechanisms of lncRNAs that are involved in hepatocarcinogenesis have not been fully explored. Methods: In this study, we profiled lncRNA expression in 127 pairs of HCC and nontumor liver tissues (a Discovery Cohort) using a custom microarray. The expression and clinical significance of lncCSMD1-1 were then validated with qRT-PCR and COX regression analysis in a Validation Cohort (n=260) and two External Validation Cohorts (n=92 and n=124, respectively). In vitro and in vivo assays were performed to explore the biological effects of lncCSMD1-1 on HCC cells. The interaction of lncCSMD1-1 with MYC was identified by RNA pull-down and RNA immunoprecipitation. The role of LncCSMD1-1 in the degradation of MYC protein was also investigated. Results: With microarray, we identified a highly upregulated lncRNA, lncCSMD1-1, which was associated with tumor progression and poor prognosis in the Discovery Cohort, and validated in another 3 HCC cohorts. Consistently, ectopic expression of lncCSMD1-1 notably promotes cell proliferation, migration, invasion, tumor growth and metastasis of HCC cells in in vitro and in vivo experiments. Gene expression profiling on HCC cells and gene sets enrichment analysis indicated that the MYC target gene set was significantly enriched in HCC cells overexpressing lncCSMD1-1, and lncCSMD1-1 was found to directly bind to MYC protein in the nucleus of HCC cells, which resulted in the elevation of MYC protein. Mechanistically, lncCSMD1-1 interacted with MYC protein to block its ubiquitin-proteasome degradation pathway, leading to activation of its downstream target genes. Conclusion: lncCSMD1-1 is upregulated in HCC and promotes progression of HCC by activating the MYC signaling pathway. These results provide the evidence that lncCSMD1-1 may serve as a novel prognostic marker and potential therapeutic target for HCC.

Liu J ，Xu R ，Mai SJ ，Ma YS ，Zhang MY ，Cao PS ，Weng NQ ，Wang RQ ，Cao D ，Wei W ，Guo RP ，Zhang YJ ，Xu L ，Chen MS ，Zhang HZ ，Huang L ，Fu D ，Wang HY ... -  《Theranostics》

Long noncoding RNA CPS1-IT1 suppresses the metastasis of hepatocellular carcinoma by regulating HIF-1α activity and inhibiting epithelial-mesenchymal transition.

Wang TH ，Yu CC ，Lin YS ，Chen TC ，Yeh CT ，Liang KH ，Shieh TM ，Chen CY ，Hsueh C ... -  《Oncotarget》

ID1 overexpression promotes HCC progression by amplifying the AURKA/Myc signaling pathway.

Wu M ，Zhou Y ，Fei C ，Chen T ，Yin X ，Zhang L ，Ren Z ... -  《-》

Six-long non-coding RNA signature predicts recurrence-free survival in hepatocellular carcinoma.

Gu JX ，Zhang X ，Miao RC ，Xiang XH ，Fu YN ，Zhang JY ，Liu C ，Qu K ... -  《-》

A novel lncRNA MCM3AP-AS1 promotes the growth of hepatocellular carcinoma by targeting miR-194-5p/FOXA1 axis.

Wang Y ，Yang L ，Chen T ，Liu X ，Guo Y ，Zhu Q ，Tong X ，Yang W ，Xu Q ，Huang D ，Tu K ... -  《Molecular Cancer》